MY161749A - Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use - Google Patents

Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use

Info

Publication number
MY161749A
MY161749A MYPI2012002250A MYPI2012002250A MY161749A MY 161749 A MY161749 A MY 161749A MY PI2012002250 A MYPI2012002250 A MY PI2012002250A MY PI2012002250 A MYPI2012002250 A MY PI2012002250A MY 161749 A MY161749 A MY 161749A
Authority
MY
Malaysia
Prior art keywords
compound
methods
preparation
pharmaceutical compositions
certain novel
Prior art date
Application number
MYPI2012002250A
Other languages
English (en)
Inventor
Wei-Guo Su
Zhenping Tian
Weihan Zhang
Hong Jia
Yumin Cui
Yongxin Ren
Yang Sai
Zhenping Wu
Wenji Li
Jiangyong Shao
Original Assignee
Hutchison Medipharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44029398&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY161749(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hutchison Medipharma Ltd filed Critical Hutchison Medipharma Ltd
Publication of MY161749A publication Critical patent/MY161749A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
MYPI2012002250A 2009-11-23 2010-11-23 Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use MY161749A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2009101992592A CN102070618B (zh) 2009-11-23 2009-11-23 一种化合物及其晶体

Publications (1)

Publication Number Publication Date
MY161749A true MY161749A (en) 2017-05-15

Family

ID=44029398

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2012002250A MY161749A (en) 2009-11-23 2010-11-23 Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use

Country Status (19)

Country Link
US (2) US8658658B2 (en:Method)
EP (1) EP2504331B1 (en:Method)
JP (1) JP5758399B2 (en:Method)
KR (1) KR101513784B1 (en:Method)
CN (2) CN102070618B (en:Method)
AU (1) AU2010321366B2 (en:Method)
BR (1) BR112012012138B1 (en:Method)
CA (1) CA2781066C (en:Method)
DK (1) DK2504331T3 (en:Method)
ES (1) ES2529105T3 (en:Method)
IN (1) IN2012DN04868A (en:Method)
MX (1) MX2012005926A (en:Method)
MY (1) MY161749A (en:Method)
NZ (1) NZ600266A (en:Method)
PH (1) PH12012500992A1 (en:Method)
PL (1) PL2504331T3 (en:Method)
PT (1) PT2504331E (en:Method)
RU (1) RU2507203C1 (en:Method)
WO (1) WO2011060746A1 (en:Method)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102070618B (zh) 2009-11-23 2013-08-21 和记黄埔医药（上海）有限公司 一种化合物及其晶体
JP6619756B2 (ja) * 2014-06-19 2019-12-11 メリアル インコーポレイテッド インドール誘導体を含む殺寄生虫性組成物、寄生虫駆除方法及びこれらの使用
CN105985326B (zh) * 2015-02-16 2020-04-14 上海宣创生物科技有限公司 嘧啶衍生物晶型ⅲ及其制备方法和用途
WO2016187767A1 (en) * 2015-05-25 2016-12-01 Hutchison Medipharma Limited Pharmaceutical compositions and use thereof
US20190276439A1 (en) * 2016-11-18 2019-09-12 Hutchison Medipharma Limited Method of treating solid tumors
JP2020164434A (ja) * 2019-03-28 2020-10-08 上野製薬株式会社 ２，６−ナフタレンビス（２−オキサゾリン）の製造方法
WO2021180027A1 (zh) * 2020-03-09 2021-09-16 和记黄埔医药（上海）有限公司 抗pd-1抗体和多受体酪氨酸激酶抑制剂的药物组合及其使用方法
JP2024515630A (ja) * 2021-04-12 2024-04-10 ミトイミューン・セラピューティクス・インコーポレイテッド ５－［（１，１－ジオキシド－４－チオモルホリニル）メチル］－２－フェニル－ｎ－（テトラヒドロ－２ｈ－ピラン－４－イル）－１ｈ－インドール－７－アミンの新規結晶形

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2558915A1 (en) * 2004-03-30 2005-10-13 Taisho Pharmaceutical Co., Ltd. Pyrimidine derivatives and methods of treatment related to the use thereof
EP1934200A1 (en) 2005-09-15 2008-06-25 Merck & Co., Inc. Tyrosine kinase inhibitors
BRPI0809715A2 (pt) * 2007-04-16 2019-11-05 Hutchison Medipharma Entpr Ltd "composto, método de tratamento de um distúrbio relacionado com a angiogênese,método de inibição da atividade de receptor de domínio de inserto de quinase, método de inibição de angiogênese e método de tratamento de degeneração macular"
CN101289444B (zh) * 2007-04-16 2012-01-04 和记黄埔医药（上海）有限公司 一种嘧啶衍生物及其医药用途
US7737157B2 (en) * 2008-08-29 2010-06-15 Hutchison Medipharma Enterprises Limited Pyrimidine compounds
CN102070618B (zh) 2009-11-23 2013-08-21 和记黄埔医药（上海）有限公司 一种化合物及其晶体

Also Published As

Publication number Publication date
EP2504331B1 (en) 2014-11-12
CN102648194B (zh) 2014-10-29
DK2504331T3 (en) 2014-12-08
KR20120097526A (ko) 2012-09-04
ES2529105T3 (es) 2015-02-16
IN2012DN04868A (en:Method) 2015-09-25
CN102648194A (zh) 2012-08-22
US20140200232A1 (en) 2014-07-17
CN102070618B (zh) 2013-08-21
MX2012005926A (es) 2012-11-23
BR112012012138A2 (pt) 2017-03-07
NZ600266A (en) 2014-06-27
AU2010321366A1 (en) 2012-06-14
EP2504331A1 (en) 2012-10-03
JP2013511475A (ja) 2013-04-04
CN102070618A (zh) 2011-05-25
AU2010321366B2 (en) 2014-07-24
US8946249B2 (en) 2015-02-03
PT2504331E (pt) 2015-02-20
US8658658B2 (en) 2014-02-25
EP2504331A4 (en) 2013-04-17
PH12012500992A1 (en) 2016-09-09
PL2504331T3 (pl) 2015-04-30
US20120270889A1 (en) 2012-10-25
JP5758399B2 (ja) 2015-08-05
RU2507203C1 (ru) 2014-02-20
CA2781066C (en) 2014-09-16
CA2781066A1 (en) 2011-05-26
RU2012126112A (ru) 2013-12-27
WO2011060746A1 (en) 2011-05-26
BR112012012138B1 (pt) 2023-02-07
AU2010321366A8 (en) 2012-07-05
KR101513784B1 (ko) 2015-04-20

Similar Documents

Publication Publication Date Title
MY193277A (en) Certain amino-pyrimidines, compositions thereof, and methods for their use
MY149731A (en) Compounds
MY187718A (en) Pharmaceutical formulations
GEP20227397B (en) Inhibitors of influenza viruses replication
MX2013003019A (es) Compuestos de azabenzotiazol, composiciones y metodos de uso.
MY183312A (en) Pharmaceutical formulation
TN2012000152A1 (en) Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes
MX336071B (es) Formulaciones intravenosas de antagonistas de neurocinina 1.
IN2012DN03182A (en:Method)
TN2012000248A1 (en) Novel spiropiperidine compounds
MY161749A (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
WO2010128050A3 (en) Dihydroorotate - dehydrogenasee inhibitors as virostatic compounds
MY165918A (en) Heterocyclic sulfonamides, uses and pharmaceutical compositions thereof
MX338551B (es) Nuevos compuestos de piridina fusionada como inhibidores de caseina quinasa.
MY160392A (en) Triptolide prodrugs
WO2012135615A3 (en) Enopeptins, uses thereof, and methods of synthesis thereto
MX353209B (es) Antagonistas d2, metodos de sintesis y metodos de uso.
UA99787C2 (en) Lactams as beta secretase inhibitors
TN2012000105A1 (en) Spirolactam derivatives and uses of same
WO2010123545A3 (en) Angiogenesis inhibitors
IN2012DN01292A (en:Method)
MX2013011926A (es) Derivados de glicosido y usos de los mismos.
MX2013009386A (es) Nuevos compuestos de azaespirodecanona.
WO2012015687A3 (en) Drug-ligand conjugates, synthesis thereof, and intermediates thereto
GEP20156269B (en) New secondary 8-hydroxyquinoline-7- carboxamide derivatives